Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.

about

Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.

Item

http://www.wikidata.org/entity/Q48319171

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Is it possible to improve prog ...... significance of comorbidities.

@en

Is it possible to improve prog ...... significance of comorbidities.

@nl

type

Item

label

Is it possible to improve prog ...... significance of comorbidities.

@en

Is it possible to improve prog ...... significance of comorbidities.

@nl

prefLabel

Is it possible to improve prog ...... significance of comorbidities.

@en

Is it possible to improve prog ...... significance of comorbidities.

@nl

P1476

Is it possible to improve prog ...... significance of comorbidities.

@en

P2093

Aleksandra Sretenovic

http://www.w3.org/2001/XMLSchema#string

Biljana Mihaljevic

http://www.w3.org/2001/XMLSchema#string

Bosko Andjelic

http://www.w3.org/2001/XMLSchema#string

Goran Trajkovic

http://www.w3.org/2001/XMLSchema#string

Jelena Bila

http://www.w3.org/2001/XMLSchema#string

Jelena Jelicic

http://www.w3.org/2001/XMLSchema#string

Mihailo Smiljanic

http://www.w3.org/2001/XMLSchema#string

Milena Todorovic Balint

http://www.w3.org/2001/XMLSchema#string

Olivera Markovic

http://www.w3.org/2001/XMLSchema#string

Vesna Nikolic

http://www.w3.org/2001/XMLSchema#string

P2860

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Nonparametric Estimation from Incomplete Observations

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP

A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.

Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte.

Cumulative illness rating scale.

P304

267-276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-3170-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Vojin Vukovic

Ivan Petković

Darko Antic

P577

2017-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29130134

http://www.w3.org/2001/XMLSchema#string